Skip to main content

View full-text article in PMC

. 2017 Mar 29;17:116. doi: 10.1186/s12888-017-1279-1

Table 3.

Crude and adjusted mean Cito-test scores for different methylphenidate treatment characteristics

1. MPH treatment	School performance
1. MPH treatment	Crude M ± SD	Adjusted^a M ± SE	n	p value
Current users	532.80 ± 9.44	532.58 ± .48	377	<0.001***
Never users	534.71 ± 9.47	534.72 ± .11	7295	<0.001***
2. Past versus current users	School performance
2. Past versus current users	Crude M ± SD	Adjusted^a M ± SE	n	p value
Current users (n = 377)	532.80 ± 9.44	532.58 ± .48	377	.470
Past users (n = 64)	531.52 ± 10.70	531.67 ± 1.15	64	.470
3. Dosage of MPH treatment	School performance
3. Dosage of MPH treatment	Crude M ± SD	Adjusted^a M ± SE	n	p value
≤ 0.999 NDDD/Day	533.17 ± 9.60	533.16 ± .66	202	.498
> 0.999 NDDD/Day	532.44 ± 9.28	532.45 ± .81	132	.498
4. Start of MPH treatment	School performance
4. Start of MPH treatment	Crude M ± SD	Adjusted^a M ± SE	n	p value
Late start ≤12 months	536.37 ± 8.62	536.94 ± 1.51	38	.004**
Early start >12 months	532.40 ± 9.46	532.33 ± .50	339	.004**
5. Concurrent treatment	School performance
5. Concurrent treatment	Crude M ± SD	Adjusted^a M ± SE	n	p value
Only MPH	532.72 ± 9.45	532.70 ± .497	347	.937
MPH + AP	532.47 ± 9.71	532.87 ± 2.13	19	.937
Only asthma medication	537.10 ± 8.52	536.90 ± .865	100	.845
MPH + asthma medication	535.64 ± 8.94	537.49 ± 2.86	11	.845

Abbreviations: M, mean; SD, standard deviation; SE, standard error; n; sample size*Significant at the .05 level

**Significant at the 0.01 level

***Significant at the 0.001 level

^aAdjusted for sex, ethnicity, parent household, and household income